Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
Study sponsor: TG Therapeutics, Inc. · TGTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-12-20Actual
Enrollment · participants277Actual
Source updated2024-04-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.